ZTlido Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ZTlido Growth

1. Strong commercial momentum and accelerating sales growth

• 2023 gross sales: ~USD 140-150 million vs ~USD 96 million in 2022 (~46-56% YoY growth)
• YTD Nov 2023 sales: ~USD 125-135 million vs USD 84.6 million in 2022
• Q1 2024 sales: ~USD 34-38 million vs USD 27.5 million in Q1 2023 (~24-38% growth)
• Demonstrates strong adoption curve and sustained double-digit growth, positioning ZTlido as a key revenue driver for Scilex.

2. Expanding prescription share and physician adoption

• ZTlido became the most prescribed branded non-opioid pain therapy by pain specialists
• New prescription (NRx) market share increased from 11.8% (Oct 2022) to 14.2% (Oct 2023)
• Indicates rapid physician uptake and competitive displacement of other branded pain therapies.

3. Favorable non-opioid positioning amid opioid crisis

• ZTlido is a non-opioid topical therapy for post-herpetic neuralgia (PHN)
• Increasing clinical and regulatory emphasis on opioid-sparing pain management supports adoption.
• Structural tailwind as healthcare systems shift away from opioids, benefiting safer alternatives like ZTlido.

4. Differentiated formulation and product advantages

• Designed to overcome limitations of traditional lidocaine patches with:
• Improved adhesion and consistent delivery over 12 hours
• Use of ZTech technology for efficient drug delivery

5. Expanding payer access and reimbursement coverage

• Added to Tennessee Medicaid Preferred Drug List, expanding access to ~1.5 million covered lives
• Broader payer engagement strategy continues to improve formulary positioning.

6. Strong IP protection and lifecycle management

• Multiple US patents granted, including formulations and delivery methods, with protection extending to ~2031
• Protects against generic competition -> supports sustained revenue growth and pricing power

ZTlido Recent Developments

• In July 2024, Scilex Holding Company announced that that it had entered into a Memorandum of Understanding (MOU) for collaboration agreement with ACEA, a China-based company focused on the development of innovative treatments for high unmet needs. Under the terms of the MOU, ACEA may receive exclusive rights to develop and commercialize of ZTlido in mainland China, Taiwan, Hong Kong, Macau, including the current formulation and a right of first negotiation for a future next generation formulation of a 3X version of ZTlido, SP-103. The MOU provides Scilex with the opportunity to expand collaboration with ACEA across other products in Scilex's non-opioid pain management portfolio in the Greater China region.

"ZTlido Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ZTlido for approved indication like Postherpetic neuralgia; as well as potential indication like Back pain in the 7MM. A detailed picture of ZTlido's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ZTlido for approved and potential indications. The ZTlido market report provides insights about ZTlido's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ZTlido performance, future market assessments inclusive of the ZTlido market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ZTlido sales forecasts, along with factors driving its market.

ZTlido Drug Summary

ZTlido is a prescription topical analgesic patch developed by Scilex Pharmaceuticals for the treatment of postherpetic neuralgia (PHN), a chronic nerve pain condition following shingles. It contains lidocaine, a local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion channels, thereby reducing ectopic nerve discharge and pain signaling at the site of application. Designed with a thin, flexible, and adhesive system, ZTlido delivers effective drug exposure comparable to higher-strength lidocaine patches (such as 5%) while improving adhesion and patient comfort. It is applied once daily for up to 12 hours, offering targeted, non-systemic pain relief with minimal systemic absorption and a favorable safety profile, making it a convenient alternative for patients who may not tolerate oral pain medications. The report provides ZTlido's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ZTlido Market Report

The report provides insights into:

• A comprehensive product overview including the ZTlido MoA, description, dosage and administration, research and development activities in approved indications like Postherpetic neuralgia; as well as potential indication like Back pain.
• Elaborated details on ZTlido regulatory milestones and other development activities have been provided in ZTlido market report.
• The report also highlights ZTlido's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ZTlido market report also covers the patents information, generic entry and impact on cost cut.
• The ZTlido market report contains current and forecasted ZTlido sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ZTlido market report also features the SWOT analysis with analyst views for ZTlido in approved and potential indications.

Methodology:

The ZTlido market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZTlido Analytical Perspective by DelveInsight

• In-depth ZTlido Market Assessment

This ZTlido sales market forecast report provides a detailed market assessment of ZTlido for approved indication like Postherpetic neuralgia; as well as potential indication like Back pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ZTlido sales data uptil 2034.

• ZTlido Clinical Assessment

The ZTlido market report provides the clinical trials information of ZTlido for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ZTlido Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ZTlido Market Potential & Revenue Forecast

• Projected market size for the ZTlido and its key indications
• Estimated ZTlido sales potential (ZTlido peak sales forecasts)
• ZTlido Pricing strategies and reimbursement landscape

ZTlido Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ZTlido Market positioning compared to existing treatments
• ZTlido Strengths & weaknesses relative to competitors

ZTlido Regulatory & Commercial Milestones

• ZTlido Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ZTlido Clinical Differentiation

• ZTlido Efficacy & safety advantages over existing drugs
• ZTlido Unique selling points

ZTlido Market Report Highlights

• In the coming years, the ZTlido market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ZTlido companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZTlido's dominance.
• Other emerging products for Postherpetic neuralgia; as well as potential indication like Back pain are expected to give tough market competition to ZTlido and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZTlido in approved and potential indications.
• Analyse ZTlido cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ZTlido sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ZTlido in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ZTlido? How strong is ZTlido's clinical and commercial performance?
• What is ZTlido's clinical trial status in each individual indications such as Postherpetic neuralgia; as well as potential indication like Back pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZTlido Manufacturers?
• What are the key designations that have been granted to ZTlido for approved and potential indications? How are they going to impact ZTlido's penetration in various geographies?
• What is the current and forecasted ZTlido market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ZTlido in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZTlido for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ZTlido? What is the duration of therapy and what are the geographical variations in cost per patient?